Last reviewed · How we verify
Olopatadine 0.2%
Olopatadine 0.2% is a marketed product by Senju USA, Inc., positioned in the ophthalmic anti-allergy segment. The drug's key strength lies in its strong patent protection, with the key composition patent expiring in 2028. The primary risk is the potential increase in competition as the patent expiration approaches.
At a glance
| Generic name | Olopatadine 0.2% |
|---|---|
| Also known as | Pataday(TM), Pataday™, Pataday |
| Sponsor | Senju USA, Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis (PHASE2)
- Efficacy and Toxicity of Bepotastine 1,5% PF vs Olopatadine 0,2% With BAK on Allergic Conjunctivitis Treatment (PHASE4)
- DEXTENZA Therapy for Treatment of Allergic Conjunctivitis (PHASE4)
- Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese Subjects (PHASE3)
- A Comparison of the Safety and Comfort of AC-170 (PHASE1)
- Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis (PHASE3)
- Olopatadine Eye Drops and Allergy Skin Testing (NA)
- Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Olopatadine 0.2% CI brief — competitive landscape report
- Olopatadine 0.2% updates RSS · CI watch RSS
- Senju USA, Inc. portfolio CI